Vascular endothelial growth factor-D: Signaling mechanisms, biology, and clinical relevance

Growth Factors

Volumn 30, Issue 5, 2012, Pages 283-296

  Achen, Marc G ^a,b,c   Stacker, Steven A ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Molecular Imaging and Therapeutic Nuclear Medicine at Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology at University of Melbourne   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiogenesis; Clinical trial; Lymphangiogenesis; Metastasis; NSAID; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CATENIN; NEUROPILIN 1; NEUROPILIN 2; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CARDIOVASCULAR DISEASE; EMBRYO DEVELOPMENT; INFLAMMATION; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; LYMPHANGIOLEIOMYOMATOSIS; LYMPHEDEMA; METASTASIS; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TISSUE PERFUSION;

ANGIOGENESIS INHIBITORS; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

ANIMALIA;

EID: 84866909298     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.704917     Document Type: Article

References (129)

1. Achen MG, Stacker SA. 2008. Molecular control of lymphaticmetastasis. Ann NY Acad Sci 1131:225-234.
2. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF,Alitalo K, Stacker SA. 1998. Vascular endothelial growthfactor D (VEGF-D) is a ligand for the tyrosine kinases VEGFreceptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl AcadSci USA 95:548-553.
3. Achen MG, Roufail S, Domagala T, Catimel B, Nice EC,Geleick DM, Murphy R, Scott AM, Caesar C, Makinen T,Alitalo K, Stacker SA. 2000. Monoclonal antibodies to vascularendothelial growth factor-D block interactions with both VEGFreceptor-2 and VEGF receptor-3. Eur J Biochem 267:2505-2515.
4. Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K,Rogers PA, Lederman F, Roufail S, Stacker SA. 2001.Localization of vascular endothelial growth factor-D inmalignant melanoma suggests a role in tumour angiogenesis. JPathol 193:147-154.
5. Achen MG, McColl BK, Stacker SA. 2005. Focus on lymphangiogenesisin tumor metastasis. Cancer Cell 7:121-127.
6. Adams RH, Alitalo K. 2007. Molecular regulation of angiogenesisand lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478.
7. Alam A, Herault JP, Barron P, Favier B, Fons P,Delesque-Touchard N, Senegas I, Laboudie P, Bonnin J,Cassan C, Savi P, Ruggeri B, Carmeliet P, Bono F,Herbert JM. 2004. Heterodimerization with vascular endothelialgrowth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3activity. Biochem Biophys Res Commun 324:909-915.
8. Algra AM, Rothwell PM. 2012. Effects of regular aspirin on longtermcancer incidence and metastasis: A systematic comparisonof evidence from observational studies versus randomised trials.Lancet Oncol 13:518-527.
9. Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S,Leppanen VM, Jeltsch M, Yla-Herttuala S, Alitalo K. 2009.Activated forms of VEGF-C and VEGF-D provide improvedvascular function in skeletal muscle. Circ Res 104:1302-1312.
10. Artenstein AW, Opal SM. 2011. Proprotein convertases in healthand disease. New Engl J Med 365:2507-2518.
11. Avantaggiato V, Orlandini M, Acampora D, Oliviero S, Simeone A.1998. Embryonic expression pattern of the murine figf gene,a growth factor belonging to platelet-derived growthfactor/vascular endothelial growth factor family. Mech Dev 73:221-224.
12. Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL,Karkkainen MJ, Alitalo K, Stacker SA, Achen MG. 2001a. Thespecificity of receptor binding by vascular endothelial growthfactor-D is different in mouse and man. J Biol Chem 276:19166-19171.
13. Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA,Achen MG. 2001b. Multiple forms of mouse vascularendothelial growth factor-D are generated by RNA splicingand proteolysis. J Biol Chem 276:44307-44314.
14. Baldwin ME, Stacker SA, Achen MG. 2002. Molecular control oflymphangiogenesis. Bioessays 24:1030-1040.
15. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML,Grail D, Kubo H, Stacker SA, Achen MG. 2005. Vascularendothelial growth factor D is dispensable for development ofthe lymphatic system. Mol Cell Biol 25:2441-2449.
16. Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ,Jeltsch M, Petrova TV, Pytowski B, Stacker SA, Yla-Herttuala S,Jackson DG, Alitalo K, McDonald DM. 2005. Pathogenesis ofpersistent lymphatic vessel hyperplasia in chronic airwayinflammation. J Clin Invest 115:247-257.
17. Bazigou E, Xie S, Chen C, Weston A, Miura N, Sorokin L,Adams R, Muro AF, Sheppard D, Makinen T. 2009. Integrinalpha9is required for fibronectin matrix assembly duringlymphatic valve morphogenesis. Dev Cell 17:175-186.
18. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F,Casanovas O, Duarte A, Pytowski B, Adams RH. 2012.Notch-dependent VEGFR3 upregulation allows angiogenesiswithout VEGF-VEGFR2 signalling. Nature 484:110-114.
19. Bhardwaj S, Roy H, Gruchala M, Viita H, Kholova I, Kokina I,Achen MG, Stacker SA, Hedman M, Alitalo K, Yla-Herttuala S.2003. Angiogenic responses of vascular endothelial growthfactors in periadventitial tissue. Hum Gene Ther 14:1451-1562.
20. Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG,Stacker SA, Carnevale KA, Siemionow M, Deitcher SR,DiCorleto PE. 2002. Adenovirus encoding vascular endothelialgrowth factor-D induces tissue-specific vascular patterns in vivo.Blood 99:4434-4442.
21. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH,Claesson-Welsh L, Alitalo K. 1998. Vascular endothelial growthfactor C induces angiogenesis in vivo. Proc Natl Acad Sci USA95:14389-14394.
22. CauntM,MakJ, LiangWC,Stawicki S,PanQ,Tong RK,Kowalski J,Ho C, Reslan HB, Ross J, Berry L, Kasman I, Zlot C, Cheng Z,Le Couter J, Filvaroff EH, Plowman G, Peale F, French D,Carano R, Koch AW, Wu Y, Watts RJ, Tessier-Lavigne M,Bagri A. 2008. Blocking neuropilin-2 function inhibits tumor cellmetastasis. Cancer Cell 13:331-342.
23. Chretien M, Seidah NG, Basak A, Mbikay M. 2008. Proproteinconvertases as therapeutic targets. Expert Opin Ther Targets 12:1289-1300.
24. Crawford Y, Ferrara N. 2009. VEGF inhibition: Insights frompreclinical and clinical studies. Cell Tissue Res 335:261-269.
25. Davydova N, Roufail S, Streltsov VA, Stacker SA, AchenMG. 2011.The VD1 neutralizing antibody to vascular endothelial growthfactor-D: Binding epitope and relationship to receptor binding.J Mol Biol 407:581-593.
26. Davydova N, Streltsov VA, Roufail S, Lovrecz GO, Stacker SA,Adams TE, Achen MG. 2012. Preparation of human vascularendothelial growth factor-D for structural and preclinicaltherapeutic studies. Protein Expr Purif 82:232-239.
27. DebinskiW, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E,Gillespie GY, Gibo DM. 2001. VEGF-D is an X-linked/AP-1regulated putative onco-angiogen in human glioblastoma multiforme.Mol Med 7:598-608.
28. Dignam SS, Case ST. 1990. Balbiani ring 3 in Chironomus tentansencodes a 185-kDa secretory protein which is synthesizedthroughout the fourth larval instar. Gene 88:133-140.
29. Farnsworth RH, Karnezis T, Shayan R, Matsumoto M, Nowell CJ,Achen MG, Stacker SA. 2011. A role for bone morphogenicprotein-4 in vascular endothelial growth factor-D mediatedtumor growth, metastasis and vessel remodelling. Cancer Res71:6547-6557.
30. Fuster V, Charlton P, Boyd A. 2001. Clinical protocol. A phase IIb,randomized, multicenter, double-blind study of the efficacy andsafety of Trinam (EG004) in stenosis prevention at the graft-veinanastomosis site in dialysis patients. Hum Gene Ther 12:2025-2027.
31. Girling JE, Donoghue JF, Lederman FL, Cann LM, Achen MG,Stacker SA, Rogers PA. 2010. Vascular endothelial growthfactor-D over-expressing tumor cells induce differential effectson uterine vasculature in a mouse model of endometrial cancer.Reprod Biol Endocrinol 8:84.
32. Glasgow CG, Avila NA, Lin JP, Stylianou MP,Moss J. 2009. Serumvascular endothelial growth factor-D levels in patients withlymphangioleiomyomatosis reflect lymphatic involvement.Chest 135:1293-1300.
33. Haiko P, Makinen T, Keskitalo S, Taipale J, Karkkainen MJ,Baldwin ME, Stacker SA, Achen MG, Alitalo K. 2008. Deletionof vascular endothelial growth factor C (VEGF-C) and VEGF-Dis not equivalent to VEGF receptor 3 deletion in mouse embryos.Mol Cell Biol 28:4843-4850.
34. Hajrasouliha AR, Funaki T, Sadrai Z, Hattori T, Chauhan SK,Dana R. 2012. Vascular endothelial growth factor-C promotesalloimmunity by amplifying antigen-presenting cell maturationand lymphangiogenesis. Invest Ophthalmol Vis Sci 53:1244-1250.
35. Halford MM, Tebbutt NC, Desai J, Achen MG, Stacker SA. 2012.Towards the biomarker-guided rational use of anti-angiogenicagents in the treatment of metastatic colorectal cancer.Colorectal Cancer 1:149-161.
36. Harris NC, Paavonen K, Davydova N, Roufail S, Sato T, Zhang YF,Karnezis T, Stacker SA, Achen MG. 2011. Proteolyticprocessing of vascular endothelial growth factor-D is essentialfor its capacity to promote the growth and spread of cancer.FASEB J 25:2615-2625.
37. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S,Takahashi T, Alitalo K. 2002. Suppression of tumor lymphangiogenesisand lymph node metastasis by blocking vascularendothelial growth factor receptor 3 signaling. J Natl Cancer Inst94:819-825.
38. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T,Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K.2005. Vascular endothelial cell growth factor receptor3-mediated activation of lymphatic endothelium is crucial fortumor cell entry and spread via lymphatic vessels. Cancer Res65:4739-4746.
39. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D,Hankinson SE. 2010. Aspirin intake and survival after breastcancer. J Clin Oncol 28:1467-1472.
40. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K,Detmar M. 2010. Stimulation of lymphangiogenesis viaVEGFR-3 inhibits chronic skin inflammation. J Exp Med 207:2255-2269.
41. Huggenberger R, Siddiqui SS, Brander D, Ullmann S,Zimmermann K, Antsiferova M, Werner S, Alitalo K,DetmarM.2011.Animportant role of lymphatic vessel activationin limiting acute inflammation. Blood 117:4667-4678.
42. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T,Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R,Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil,and leucovorin for metastatic colorectal cancer. New Engl J Med350:2335-2342.
43. Jenkins NA, Woollatt E, Crawford J, Gilbert DJ, Baldwin ME,Sutherland GR, Copeland NG, Achen MG. 1997. Mapping ofthe gene for vascular endothelial growth factor-D in mouse andman to the X chromosome. Chromosome Res 5:502-505.
44. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I.2004. Vascular endothelial growth factor (VEGF)-D andVEGF-A differentially regulate KDR-mediated signaling andbiological function in vascular endothelial cells. J Biol Chem279:36148-36157.
45. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E,Saksela O, Kalkkinen N, Alitalo K. 1996. A novel vascularendothelial growth factor, VEGF-C, is a ligand for the Flt-4(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.EMBO J 15:290-298.
46. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y,Saksela O, Kalkkinen N, Alitalo K. 1997. Proteolytic processingregulates receptor specificity and activity of VEGF-C. EMBO J16:3898-3911.
47. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E,Sarkar S. 2005. Combined analysis of efficacy: The addition ofbevacizumab to fluorouracil/leucovorin improves survival forpatients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712.
48. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J,Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H,Betsholtz C, Alitalo K. 2004. Vascular endothelial growth factorC is required for sprouting of the first lymphatic vessels fromembryonic veins. Nat Immunol 5:74-80.
49. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC,Ardipradja K, Zhang YF, Williams SP, Farnsworth RH,Chai MG, Rupasinghe TW, Tull DL, Baldwin ME, Sloan EK,Fox SB, Achen MG, Stacker SA. 2012. VEGF-D promotestumor metastasis by regulating prostaglandins produced by thecollecting lymphatic endothelium. Cancer Cell 21:181-195.
50. Karpanen T, Egeblad M, KarkkainenMJ, KuboH, Yla-Herttuala S,Jaattela M, Alitalo K. 2001. Vascular endothelial growth factor Cpromotes tumor lymphangiogenesis and intralymphatic tumorgrowth. Cancer Res 61:1786-1790.
51. Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H,Neufeld G, Tamagnone L, Alitalo K. 2006a. Functionalinteraction of VEGF-C and VEGF-D with neuropilin receptors.FASEB J 20:1462-1472.
52. Karpanen T, Wirzenius M, Makinen T, Veikkola T, Haisma HJ,Achen MG, Stacker SA, Pytowski B, Yla-Herttuala S, Alitalo K.2006b. Lymphangiogenic growth factor responsiveness ismodulated by postnatal lymphatic vessel maturation. Am JPathol 169:708-718.
53. Kholova I, Koota S, Kaskenpaa N, Leppanen P, Narvainen J,Kavec M, Rissanen TT, Hazes T, Korpisalo P, Grohn O,Yla-Herttuala S. 2007. Adenovirus-mediated gene transfer ofhuman vascular endothelial growth factor-D induces transientangiogenic effects in mouse hind limb muscle. Hum Gene Ther18:232-244.
54. Koch M, Dettori D, Van Nuffelen A, Souffreau J, Marconcini L,Wallays G,Moons L, Bruyere F, Oliviero S, Noel A, Foidart JM,Carmeliet P, Dewerchin M. 2009. VEGF-D deficiency in micedoes not affect embryonic or postnatal lymphangiogenesis butreduces lymphatic metastasis. J Pathol 219:356-364.
55. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. 2011.Signal transduction by vascular endothelial growth factorreceptors. Biochem J 437:169-183.
56. Kopfstein L, Veikkola T, Djonov VG, Baeriswyl V, Schomber T,Strittmatter K, Stacker SA, Achen MG, Alitalo K, Christofori G.2007. Distinct roles of vascular endothelial growth factor-D inlymphangiogenesis and metastasis. Am J Pathol 170:1348-1361.
57. Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T,Hayashi S, Minami M, Uekusa T, Fukuchi Y, Suda K. 2004.Lymphangiogenesis in lymphangioleiomyomatosis:Its implication in the progression of lymphangioleiomyomatosis.Am J Surg Pathol 28:1007-1016.
58. Kumasaka T, Seyama K, Mitani K, Souma S, Kashiwagi S,Hebisawa A, Sato T, Kubo H, Gomi K, Shibuya K, Fukuchi Y,Suda K. 2005. Lymphangiogenesis-mediated shedding of LAMcell clusters as a mechanism for dissemination in lymphangioleiomyomatosis.Am J Surg Pathol 29:1356-1366.
59. Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B,Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K.2007. Vascular endothelial growth factor receptor 3 is involved intumor angiogenesis and growth. Cancer Res 67:593-599.
60. Lahteenvuo M, Honkonen K, Tervala T, Tammela T, Suominen E,Lahteenvuo J, Kholova I, Alitalo K, Yla-Herttuala S, Saaristo A.2011. Growth factor therapy and autologous lymph nodetransfer in lymphedema. Circulation 123:613-620.
61. Leppanen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U,Alitalo K, Yla-Herttuala S. 2005. Gene transfers of vascularendothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelialgrowth factor-D have no effects on atherosclerosis in hypercholesterolemiclow-density lipoprotein-receptor/apolipoproteinB48-deficient mice. Circulation 112:1347-1352.
62. Leppanen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N,Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K,Alitalo K. 2010. Structural determinants of growth factorbinding and specificity by VEGF receptor 2. Proc Natl Acad SciUSA 107:2425-2430.
63. Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K,Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K,Alitalo K. 2011. Structural determinants of vascular endothelialgrowth factor-D receptor binding and specificity. Blood 117:1507-1515.
64. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y,Eigenbrot C, Yin J, Koch AW, Wu X, Ferrara N, Bagri A,Tessier-Lavigne M, Watts RJ, Wu Y. 2007. Function blockingantibodies to neuropilin-1 generated from a designed humansynthetic antibody phage library. J Mol Biol 366:815-829.
65. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B,Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K.2005. Inhibition of lymphogenous metastasis using adenoassociatedvirus-mediated gene transfer of a soluble VEGFR-3decoy receptor. Cancer Res 65:6901-6909.
66. Makinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI,Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, NishikawaS, Yla-Herttuala S, Alitalo K. 2001a. Inhibition of lymphangiogenesiswith resulting lymphedema in transgenic mice expressingsoluble VEGF receptor-3. Nat Med. 7:199-205.
67. Makinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B,Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D,Stacker SA, Achen MG, Alitalo K. 2001b. Isolated lymphaticendothelial cells transduce growth, survival and migratorysignals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762-4773.
68. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, PrevoR, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L,Alitalo K, Christofori G, Pepper MS. 2001. Vascular endothelialgrowth factor-C-mediated lymphangiogenesis promotes tumourmetastasis. EMBO J 20:672-682.
69. Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A,Ziche M, Bussolino F, Oliviero S. 1999. c-fos-induced growthfactor/vascular endothelial growth factor D induces angiogenesisin vivo and in vitro. Proc Natl Acad Sci USA 96:9671-9676.
70. McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL,Simpson RJ, Alitalo K, Stacker SA, Achen MG. 2003. Plasminactivates the lymphangiogenic growth factors VEGF-C andVEGF-D. J Exp Med 198:863-868.
71. McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N,Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML,Rogers PA, Alitalo K, Stacker SA, Achen MG. 2007. Proproteinconvertases promote processing of VEGF-D, a critical step forbinding the angiogenic receptor VEGFR-2. FASEB J 21:1088-1098.
72. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC. 2011. Efficacy and safety of sirolimus inlymphangioleiomyomatosis. New Engl J Med 364:1595-1606.
73. McDonald NQ, HendricksonWA. 1993. A structural superfamily ofgrowth factors containing a cystine knot motif. Cell 73:421-424.
74. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A. 1993. High affinity VEGFbinding and developmental expression suggest Flk-1 as a majorregulator of vasculogenesis and angiogenesis. Cell 72:835-846.
75. Mitani K, Kumasaka T, Takemura H, Hayashi T, Gunji Y, Kunogi M, Akiyoshi T, Takahashi K, Suda K, Seyama K. 2009.Cytologic, immunocytochemical and ultrastructural characterizationof lymphangioleiomyomatosis cell clusters in chylouseffusions of patients with lymphangioleiomyomatosis. ActaCytol 53:402-409.
76. Ny A, Koch M, Vandevelde W, Schneider M, Fischer C, Diez-Juan A, Neven E, Geudens I, Maity S, Moons L, Plaisance S, Lambrechts D, Carmeliet P, Dewerchin M. 2008.Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood112:1740-1749.
77. Orlandini M, Oliviero S. 2001. In fibroblasts Vegf-D expression isinduced by cell-cell contact mediated by cadherin-11. J BiolChem 276:6576-6581.
78. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. 1996.Identification of a c-fos-induced gene that is related to theplatelet-derived growth factor/vascular endothelial growth factorfamily. Proc Natl Acad Sci USA 93:11675-11680.
79. OrlandiniM, Semboloni S, Oliviero S. 2003. Beta-catenin inverselyregulates vascular endothelial growth factor-D mRNA stability.J Biol Chem 278:44650-44656.
80. Orlandini M, Spreafico A, Bardelli M, Rocchigiani M, Salameh A, Nucciotti S, Capperucci C, Frediani B, Oliviero S. 2006.Vascular endothelial growth factor-D activates VEGFR-3expressed in osteoblasts inducing their differentiation. J BiolChem 281:17961-17967.
81. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, Ross S, Cheng Z, Le Couter J, Plowman G, Peale F, Koch AW, Wu Y, Bagri A, Tessier-Lavigne M, Watts RJ. 2007. Blocking neuropilin-1function has an additive effect with anti-VEGF to inhibit tumorgrowth. Cancer Cell 11:53-67.
82. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K. 2000. VEGF-C andVEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues.FASEB J 14:2087-2096.
83. Persaud K, Tille JC, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao HQ, Brennan LA, Witte L, Pepper MS, Pytowski B. 2004.Involvement of the VEGF receptor 3 in tubular morphogenesisdemonstrated with a human anti-human VEGFR-3 monoclonalantibody that antagonizes receptor activation by VEGF-C. J CellSci 117:2745-2756.
84. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA. 2005. Complete andspecific inhibition of adult lymphatic regeneration by a novelVEGFR-3 neutralizing antibody. J Natl Cancer Inst 97:14-21.
85. Rinderknecht M, Villa A, Ballmer-Hofer K, Neri D, Detmar M.2010. Phage-derived fully human monoclonal antibody fragmentsto human vascular endothelial growth factor-C block itsinteraction with VEGF receptor-2 and 3. PLoS One 5:e11941.
86. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholova I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Yla-Herttuala S. 2003. VEGF-D is thestrongest angiogenic and lymphangiogenic effector amongVEGFs delivered into skeletal muscle via adenoviruses. CircRes 92:1098-1106.
87. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. 2010. Long-term effect of aspirin oncolorectal cancer incidence and mortality: 20-year follow-up offive randomised trials. Lancet 376:1741-1750.
88. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. 2011. Effect of daily aspirin on long-term risk ofdeath due to cancer: Analysis of individual patient data fromrandomised trials. Lancet 377:31-41.
89. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z.2012. Effect of daily aspirin on risk of cancer metastasis: A studyof incident cancers during randomised controlled trials. Lancet379:1591-1601.
90. Roy H, Bhardwaj S, Babu M, Lahteenvuo JE, Yla-Herttuala S.2010. VEGF-DdeltaNdeltaC mediated angiogenesis in skeletalmuscles of diabetic WHHL rabbits. Eur J Clin Invest 40:422-432.
91. Rutanen J, Leppanen P, Tuomisto TT, Rissanen TT, HiltunenMO, Vajanto I, Niemi M, Hakkinen T, Karkola K, Stacker SA, Achen MG, Alitalo K, Yla-Herttuala S. 2003. Vascularendothelial growth factor-D expression in human atheroscleroticlesions. Cardiovasc Res 59:971-979.
92. Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, SilvennoinenP, Kivela A, Hedman A, Hedman M, Heikura T, Orden MR, Stacker SA, Achen MG, Hartikainen J, Yla-Herttuala S. 2004.Adenoviral catheter-mediated intramyocardial gene transferusing the mature form of vascular endothelial growth factor-Dinduces transmural angiogenesis in porcine heart. Circulation109:1029-1035.
93. Rutanen J, Turunen AM, Teittinen M, Rissanen TT, Heikura T, Koponen JK, Gruchala M, Inkala M, Jauhiainen S, Hiltunen MO, Turunen MP, Stacker SA, Achen MG, Yla-Herttuala S. 2005. Gene transfer using the mature form ofVEGF-D reduces neointimal thickening through nitric oxidedependentmechanism. Gene Ther 12:980-987.
94. Schafer G, Wissmann C, Hertel J, Lunyak V, Hocker M. 2008.Regulation of vascular endothelial growth factor D by orphanreceptors hepatocyte nuclear factor-4 alpha and chickenovalbumin upstream promoter transcription factors 1 and 2.Cancer Res 68:457-466.
95. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. 2002. Tumorassociatedmacrophages express lymphatic endothelial growthfactors and are related to peritumoral lymphangiogenesis. Am JPathol 161:947-956.
96. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y. 2006. Vascular endothelial growthfactor-D is increased in serum of patients with lymphangioleiomyomatosis.Lymphat Res Biol 4:143-152.
97. Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T. 2010. Lymphangioleiomyomatosis: A disease involving the lymphaticsystem. Lymphat Res Biol 8:21-31.
98. Shayan R, Achen MG, Stacker SA. 2006. Lymphatic vessels incancer metastasis: Bridging the gaps. Carcinogenesis 27:1729-1738.
99. Shayan R, Karnezis T, Tsantikos E, Williams SP, Runting A, AshtonMW, Achen MG, Hibbs ML, Stacker SA. 2007. A system forquantifying the patterning of the lymphatic vasculature. GrowthFactors 25:417-425.
100. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, Seidah NG, Khatib AM. 2003. The secretoryproprotein convertases furin, PC5, and PC7 activate VEGF-C toinduce tumorigenesis. J Clin Invest 111:1723-1732.
101. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. 1998.Neuropilin-1 is expressed by endothelial and tumor cells as anisoform-specific receptor for vascular endothelial growth factor.Cell 92:735-745.
102. Song M, Yang H, Yao S, Ma F, Li Z, Deng Y, Deng H, Zhou Q, Lin S, Wei Y. 2007. A critical role of vascular endothelial growthfactor D in zebrafish embryonic vasculogenesis and angiogenesis. Biochem Biophys Res Commun 357:924-930.
103. Stacker SA, Achen MG. 2008. From anti-angiogenesis to antilymphangiogenesis:Emerging trends in cancer therapy. LymphatRes Biol 6:165-172.
104. Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, Roufail S, Simpson RJ, Moritz R, Karpanen T, Alitalo K, Achen MG. 1999a. Biosynthesis of vascular endothelial growthfactor-D involves proteolytic processing which generates noncovalenthomodimers. J Biol Chem 274:32127-32136.
105. Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF. 1999b. A mutant form of vascularendothelial growth factor (VEGF) that lacks VEGF receptor-2activation retains the ability to induce vascular permeability. J Biol Chem 274:34884-34892.
106. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. 2001. VEGF-D promotes the metastatic spread of tumor cells via thelymphatics. Nat Med. 7:186-191.
107. Stacker SA, Williams RA, Achen MG. 2004. Lymphangiogenicgrowth factors as markers of tumor metastasis. APMIS 112:539-549.
108. Tammela T, Alitalo K. 2010. Lymphangiogenesis: Molecularmechanisms and future promise. Cell 140:460-476.
109. Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K. 2007. Therapeutic differentiation and maturation oflymphatic vessels after lymph node dissection and transplantation. Nat Med 13:1458-1466.
110. Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, SchomberT, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. 2008. Blocking VEGFR-3 suppressesangiogenic sprouting and vascular network formation. Nature454:656-660.
111. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. 2011. VEGFR-3 controls tip to stalk conversion at vessel fusion sitesby reinforcing Notch signalling. Nat Cell Biol 13:1202-1213.
112. Thelen A, Scholz A, Benckert C, von Marschall Z, Schroder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S. 2008. VEGF-D promotes tumor growth and lymphatic spread in amouse model of hepatocellular carcinoma. Int J Cancer 122:2471-2481.
113. Toivanen PI, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, Markkanen JE, Laitinen OH, Airenne TT, Salminen TA, Johnson MS, Airenne KJ, Yla-Herttuala S. 2009. Novel vascular endothelial growth factor D variants withincreased biological activity. J Biol Chem 284:16037-16048.
114. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. 2001. Signalling via vascularendothelial growth factor receptor-3 is sufficient for lymphangiogenesisin transgenic mice. EMBO J 20:1223-1231.
115. Vlahakis NE, Young BA, Atakilit A, Sheppard D. 2005. Thelymphangiogenic vascular endothelial growth factors VEGF-Cand-D are ligands for the integrin alpha9beta1. J Biol Chem280:4544-4552.
116. Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, WiedenmannB, Rosewicz S. 2005. Vascular endothelial growth factor-Dinduces lymphangiogenesis and lymphatic metastasis in modelsof ductal pancreatic cancer. Int J Oncol 27:669-679.
117. Wang JF, Zhang XF, Groopman JE. 2001. Stimulation of beta1integrin induces tyrosine phosphorylation of vascular endothelialgrowth factor receptor-3 and modulates cell migration. J BiolChem 276:41950-41957.
118. Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, Cummins M, Asadi K, Price TJ, Mariadason J, Tebbutt NC. 2011. Vascular endothelial growth factors (VEGF) and VEGFreceptor expression as predictive biomarkers for benefit withbevacizumab in metastatic colorectal cancer (mCRC): Analysisof the phase III MAX study. In: 2011 ASCO Annual Meeting. J Clin Oncol 29:2011 (Suppl abstr 3531).
119. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, Murray JC. 2002. Vascular endothelial growthfactor-D expression is an independent prognostic marker forsurvival in colorectal carcinoma. Cancer Res 62:1669-1675.
120. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. 1997. Crystal structure at 1. 7 A resolution of VEGFin complex with domain 2 of the Flt-1 receptor. Cell 91:695-704.
121. Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K. 2007. Distinct vascular endothelialgrowth factor signals for lymphatic vessel enlargement andsprouting. J Exp Med 204:1431-1440.
122. Wise LM, Ueda N, Dryden NH, Fleming SB, Caesar C, Roufail S, Achen MG, Stacker SA, Mercer AA. 2003. Viral vascularendothelial growth factors vary extensively in amino acidsequence, receptor-binding specificities, and the ability toinduce vascular permeability yet are uniformly active mitogens. J Biol Chem 278:38004-38014.
123. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P. 1998. Monoclonal antibodies targeting the VEGFreceptor-2 (Flk1/KDR) as an anti-angiogenic therapeuticstrategy. Cancer Metastasis Rev 17:155-161.
124. Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, Del Toro R, Suchting S, Medvinsky A, Silva J, Yang J, Thomas JL, Koch AW, Alitalo K, Eichmann A, Bagri A. 2010. Neuropilin-2 mediates VEGF-C-induced lymphatic sproutingtogether with VEGFR3. J Cell Biol 188:115-130.
125. Yamada Y, Nezu JI, Shimane M, Hirata Y. 1997. Molecular cloningof a novel vascular endothelial growth factor, VEGF-D. Genomics 42:483-488.
126. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Umemoto M, Sakamoto T, Sato S, Mizunuma H, Smith SK. 2003. Vascularendothelial growth factor-D is an independent prognostic factorin epithelial ovarian carcinoma. Br J Cancer 88:237-244.
127. Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, Sasaki T, Miura M. 2005. Role of VEGF-C and VEGF-D inlymphangiogenesis in gastric cancer. Int J Clin Oncol 10:318-327.
128. Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX. 2010. Serum vascularendothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosisfrom other diseases. Chest 138:674-681.
129. Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z. 2004. Inhibition of both the autocrine and theparacrine growth of human leukemia with a fully humanantibody directed against vascular endothelial growth factorreceptor 2. Leuk Lymphoma 45:1887-1897.